Georgia's Online Cancer Information Center

Find A Clinical Trial

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Status
Active
Cancer Type
Colon/Rectal Cancer
Esophogeal Cancer
Stomach/ Gastric Cancer
Trial Phase
Phase I
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT03798626
Protocol IDs
CVPM087A2101 (primary)
NCI-2019-04426
2018-003952-19
Study Sponsor
Novartis Pharmaceuticals Corporation

Summary

This study will determine the pharmacodynamically-active dose of gevokizumab and the
tolerable dose and preliminary efficacy of gevokizumab in combination with the standard of
care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic
gastroesophageal cancer and metastatic renal cell carcinoma.

Eligibility

  1. Inclusion Criteria: - Metastatic disease not amenable to potentially curative surgery and with available archival tumor tissue or fresh tumor tissue biopsy. - Presence of at least 1 measurable lesion assessed by CT and/or MRI according to RECIST 1.1. For Cohort A: - First line metastatic colorectal cancer. For Cohort B: - Second line metastatic colorectal cancer that has progressed on prior chemotherapy administered for metastatic disease and which must include a fluoropyrimidine and oxaliplatin. For Cohort C: - Second line metastatic gastroesophageal cancer that has progressed on prior line of chemotherapy administered for metastatic disease, and which must include a platinum agent and fluoropyrimidine doublet. For Cohort D: - Second or third line metastatic renal cell carcinoma with a clear-cell component and has received one or two lines of treatment for metastatic disease that included an anti-angiogenic agent for at least 4 weeks with radiologic progression on that treatment. For subjects starting from Part 1a in Cohorts A and B: - Serum hs-CRP at screening = 10 mg/L. - Not requiring immediate initiation of anti-cancer therapy per investigator's best judgement. For subjects starting from Part 2 in Cohorts C and D: - Serum hs-CRP at screening = 10 mg/L. Exclusion Criteria: For All Cohorts: - Currently receiving any of the prohibited medications or has contraindications as outlined in the protocol. - Symptomatic brain metastases or brain metastases that require directed therapy (such as focal radiotherapy or surgery). - Suspected or proven immunocompromised state, or infections (as defined in the protocol). - Conditions that have a high risk of clinically significant bleeding after administration of anti-VEGF agents. - Clinically significant, uncontrolled or recent (within last 6 months) cardiovascular disease. For Cohort D: - Concomitant medications, herbal supplements, and/or fruits and their juices that are known as strong inhibitors or inducers of CYP3A4/5, and medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5. - Impairment of GI function or GI disease that may significantly alter the absorption of cabozantinib. Other protocol-defined inclusion/exclusion criteria may apply
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.